标题
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2018-10-17
DOI
10.3389/fphar.2018.01048
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- MALDI imaging facilitates new topical drug development process by determining quantitative skin distribution profiles
- (2018) David Bonnel et al. ANALYTICAL AND BIOANALYTICAL CHEMISTRY
- Autoimmunity and COPD
- (2018) Gaetano Caramori et al. CHEST
- Role of efflux transporters in the absorption, distribution and elimination in rodents of a novel PDE4 inhibitor, CHF6001
- (2018) V. Cenacchi et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Topical application of anthranilate derivatives ameliorates psoriatic inflammation in a mouse model by inhibiting keratinocyte-derived chemokine expression and neutrophil infiltration
- (2018) Zih-Chan Lin et al. FASEB JOURNAL
- Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation
- (2018) Samar H Ibrahim et al. GUT
- Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP
- (2018) Nahla E. El-Ashmawy et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice: Involvement of p38 and JNK Signaling Pathways
- (2018) Hui Yu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis
- (2018) Lu-Fei Shen et al. IRISH JOURNAL OF MEDICAL SCIENCE
- Phosphodiesterase 4 inhibitors
- (2018) Rema Zebda et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A negative allosteric modulator of PDE4D enhances learning after traumatic brain injury
- (2018) David J. Titus et al. NEUROBIOLOGY OF LEARNING AND MEMORY
- The relationship between inflammation and remodeling in childhood asthma: A systematic review
- (2018) Jose A. Castro-Rodriguez et al. PEDIATRIC PULMONOLOGY
- Year in review 2017: Chronic obstructive pulmonary disease and asthma
- (2018) Melissa J. Benton et al. RESPIROLOGY
- Intolerance to roflumilast in real-life clinical practice
- (2017) Mónica Gómez-Rodríguez et al. European Journal of Internal Medicine
- Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs
- (2017) Anna Urbanova et al. EXPERIMENTAL LUNG RESEARCH
- Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis
- (2017) Masutaka Furue et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis
- (2017) Alice C. Cheape et al. Expert Review of Clinical Immunology
- PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue
- (2017) Marco Spadaccini et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- 2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis
- (2017) Vic Ciaravino et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis
- (2017) Lawrence F. Eichenfield et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Modulation of signaling through GPCR-cAMP-PKA pathways by PDE4 depends on stimulus intensity: Possible implications for the pathogenesis of acrodysostosis without hormone resistance
- (2017) Emmanuelle Motte et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium
- (2017) Joachim H. Ficker et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Addressing the Immunopathogenesis of Atopic Dermatitis: Advances in Topical and Systemic Treatment
- (2017) Lawrence Eichenfield et al. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
- Apremilast for the treatment of Behcet’s syndrome
- (2017) Gulen Hatemi et al. Expert Opinion on Orphan Drugs
- Pathological Roles of Neutrophil-Mediated Inflammation in Asthma and Its Potential for Therapy as a Target
- (2017) Han Gao et al. Journal of Immunology Research
- Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases
- (2017) Theerasuk Kawamatawong Journal of Thoracic Disease
- Editorial: Regulation of Inflammation, Its Resolution and Therapeutic Targeting
- (2017) Mariagrazia Uguccioni et al. Frontiers in Immunology
- Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers
- (2016) Lee T. Zane et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Pharmacological Profile of GPD-1116, an Inhibitor of Phosphodiesterase 4
- (2016) Takashi Nose et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- In vivo effective dibenzo[ b , d ]furan-1-yl-thiazoles as novel PDE-4 inhibitors
- (2016) Gopalan Balasubramanian et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex
- (2016) Peter H. Schafer et al. CELLULAR SIGNALLING
- Effect of roflumilast on airway remodelling in a murine model of chronic asthma
- (2016) S. W. Kim et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Chronic inflammatory airway diseases: the central role of the epithelium revisited
- (2016) S. T. Gohy et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions
- (2016) Naisargee Parikh et al. CURRENT MEDICINAL CHEMISTRY
- The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease
- (2016) Mario Cazzola et al. Expert Opinion on Drug Discovery
- Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis
- (2016) Luca Bianchi et al. Expert Opinion on Drug Metabolism & Toxicology
- Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis
- (2016) Paola Rogliani et al. Expert Opinion On Drug Safety
- New therapeutic solutions for Behçet’s syndrome
- (2016) Antonio Vitale et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast
- (2016) Andrea Chiricozzi et al. Expert Review of Clinical Immunology
- PDE4B as a microglia target to reduce neuroinflammation
- (2016) Damien D. Pearse et al. GLIA
- Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies
- (2016) LT Zane et al. Immunotherapy
- The phosphodiesterase 4 inhibitor roflumilast augments the Th17-promoting capability of dendritic cells by enhancing IL-23 production, and impairs their T cell stimulatory activity due to elevated IL-10
- (2016) Matthias Bros et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study
- (2016) Fuminori Ohba et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design
- (2016) Chimed Jansen et al. JOURNAL OF MEDICINAL CHEMISTRY
- GS-5759, a Bifunctional β 2 -Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells
- (2016) Taruna Joshi et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study
- (2016) Jon M. Hanifin et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
- (2016) Amy S. Paller et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Advances in the treatment of cutaneous lupus erythematosus
- (2016) A Kuhn et al. LUPUS
- New insights into the immunopathogenesis of systemic lupus erythematosus
- (2016) George C. Tsokos et al. Nature Reviews Rheumatology
- Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study
- (2016) Lee T. Zane et al. PEDIATRIC DERMATOLOGY
- A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients
- (2016) D. Singh et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
- (2016) Paolo Gisondi et al. Drug Design Development and Therapy
- Psoriasis
- (2016) Jacqueline E. Greb et al. Nature Reviews Disease Primers
- The Regulation of NF-κB Subunits by Phosphorylation
- (2016) Frank Christian et al. Cells
- Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
- (2015) Melinda Gooderham et al. BIODRUGS
- Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis
- (2015) Hunar Abdulrahim et al. EXPERT OPINION ON PHARMACOTHERAPY
- Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis
- (2015) Fuminori Ohba et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner
- (2015) Michael Lehrke et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Neuroinflammation in Alzheimer's disease
- (2015) Michael T Heneka et al. LANCET NEUROLOGY
- The psoriasis drugs market
- (2015) Salman Rizvi et al. NATURE REVIEWS DRUG DISCOVERY
- Cytokines in rheumatoid arthritis — shaping the immunological landscape
- (2015) Iain B. McInnes et al. Nature Reviews Rheumatology
- Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study
- (2015) Gulen Hatemi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel therapeutic targets in rheumatoid arthritis
- (2015) Marije I. Koenders et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis
- (2014) Vlad Ratziu et al. Clinical Gastroenterology and Hepatology
- Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis
- (2014) Tsugunobu Andoh et al. EXPERIMENTAL DERMATOLOGY
- PDE inhibitors currently in early clinical trials for the treatment of asthma
- (2014) Maria Gabriella Matera et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases
- (2014) Ana Martinez et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Phosphodiesterase Inhibitors for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
- (2014) Clive P. Page INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- Effect of the phosphodiesterase 4 inhibitor E6005 on nerve growth factor elevation in irritated skin of NC/Nga mice
- (2014) Naoto Ishii et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: Inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP
- (2014) Tsugunobu Andoh et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: Results of a randomized, vehicle-controlled, multicenter clinical trial
- (2014) Masutaka Furue et al. JOURNAL OF DERMATOLOGY
- Discovery and Early Clinical Development of 2-{6-[2-(3,5-Dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a Soft-Drug Inhibitor of Phosphodiesterase 4 for Topical Treatment of Atopic Dermatitis
- (2014) Jakob Felding et al. JOURNAL OF MEDICINAL CHEMISTRY
- Advances in targeting cyclic nucleotide phosphodiesterases
- (2014) Donald H. Maurice et al. NATURE REVIEWS DRUG DISCOVERY
- The PDE4 Inhibitor HT-0712 Improves Hippocampus-Dependent Memory in Aged Mice
- (2014) Marco Peters et al. NEUROPSYCHOPHARMACOLOGY
- Atopic Dermatitis: Skin-Directed Management
- (2014) Megha M. Tollefson et al. PEDIATRICS
- The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma
- (2014) Brian R Leaker et al. BMC Pulmonary Medicine
- Apremilast for the treatment of psoriatic arthritis
- (2014) Sowmya Varada et al. Expert Review of Clinical Pharmacology
- Roflumilast in the management of chronic obstructive pulmonary disease
- (2013) M. Lipari et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Phosphodiesterase-4 Inhibitor Therapy for Lung Diseases
- (2013) Bianca Beghè et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Phosphodiesterase 4-targeted treatments for autoimmune diseases
- (2013) Neal Kumar et al. BMC Medicine
- NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-κB signalling pathways while reducing proinflammatory cytokine production
- (2013) Issaka Yougbaré et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- Phosphodiesterase-4 inhibitors: a review of current developments (2010 – 2012)
- (2013) Amadeu Gavaldà et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Pipeline for COPD drugs flows with combination candidates
- (2013) Helen Thompson NATURE MEDICINE
- Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD
- (2013) Henrik Watz et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats
- (2013) D. A. Koch et al. RHEUMATOLOGY
- Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities
- (2013) I. Tabas et al. SCIENCE
- New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast
- (2013) Andrew Palfreeman et al. Drug Design Development and Therapy
- Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease
- (2012) Ana García-Osta et al. ACS Chemical Neuroscience
- Apremilast mechanism of action and application to psoriasis and psoriatic arthritis
- (2012) Peter Schafer BIOCHEMICAL PHARMACOLOGY
- Tetomilast: new promise for phosphodiesterase-4 inhibitors?
- (2012) Stephen J Bickston et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phosphodiesterase inhibitors in inflammatory bowel disease
- (2012) Pooneh Salari et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Disease Progression in MRL/lpr Lupus-Prone Mice Is Reduced by NCS 613, a Specific Cyclic Nucleotide Phosphodiesterase Type 4 (PDE4) Inhibitor
- (2012) Thérèse Keravis et al. PLoS One
- NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues
- (2011) Issaka Yougbare et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane
- (2011) A. Crilly et al. ANNALS OF THE RHEUMATIC DISEASES
- PDE4: A Novel Target in the Treatment of Chronic Obstructive Pulmonary Disease
- (2011) J M Michalski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity
- (2011) Miki Kobayashi et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor
- (2011) Miki Kobayashi et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- GSK256066, an Exceptionally High-Affinity and Selective Inhibitor of Phosphodiesterase 4 Suitable for Administration by Inhalation: In Vitro, Kinetic, and In Vivo Characterization
- (2011) C. J. Tralau-Stewart et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- In Vivo Characterization of GSK256066, a High-Affinity Inhaled Phosphodiesterase 4 Inhibitor
- (2011) A. T. Nials et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Anthranilic acid-based inhibitors of phosphodiesterase: Design, synthesis, and bioactive evaluation
- (2011) Yih-Dih Cheng et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment
- (2010) Michel Gallant et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis
- (2010) Fiona E McCann et al. ARTHRITIS RESEARCH & THERAPY
- Discovery and structure–activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis
- (2009) Tsutomu Akama et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury
- (2009) J Cortijo et al. BRITISH JOURNAL OF PHARMACOLOGY
- Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
- (2009) PH Schafer et al. BRITISH JOURNAL OF PHARMACOLOGY
- PDE4 inhibitors: a review of current developments (2005 – 2009)
- (2009) Lluís Pagès et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease
- (2009) J.N. Gordon et al. Journal of Crohns & Colitis
- Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor
- (2009) Hon-Wah Man et al. JOURNAL OF MEDICINAL CHEMISTRY
- Effects of Roflumilast, a Phosphodiesterase-4 Inhibitor, on Hypoxia- and Monocrotaline-Induced Pulmonary Hypertension in Rats
- (2009) M. Izikki et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
- (2009) Peter MA Calverley et al. LANCET
- Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety
- (2009) Alex B Burgin et al. NATURE BIOTECHNOLOGY
- Optimization and structure–activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: Identification of MK-0873, a potent and effective PDE4 inhibitor
- (2008) Daniel Guay et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice
- (2008) Hitoshi Ichikawa et al. INFLAMMATORY BOWEL DISEASES
- MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers
- (2008) J.D. Boot et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now